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cost-effectiveness ratio (ICER) was €2059 in the base case,
varying from €1474 to €4963 according to the multi-ways sen-
sitivity analysis. CONCLUSIONS: The economic assessment
shows that TAC is cost-effective in the management of early
breast cancer in France with an ICER below the threshold com-
monly cited in such analyses.
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OBJECTIVES: CALGB conducted a randomized trial to
compare the survival duration, quality of life, and costs of
hepatic artery infusion (HAI) versus systemic chemotherapy
(SYS) as initial treatment for patients with colorectal cancer
metastatic to the liver. We evaluated the lifetime incremental cost
and beneﬁt from a third-party payer perspective alongside that
trial. METHODS: Resource use data were collected for all study
patients through 18 months, regardless of disease progression,
and a subset was followed until death. Unit costs were derived
from itemized patient bills, adjusted using department-speciﬁc
ratios of costs to charges. Utility weights were collected serially
from trial patients and used to calculate quality-adjusted sur-
vival. RESULTS: During the ﬁrst 18 months, inpatient stays
accounted for the highest proportion of overall costs (47%) in
the HAI arm, while outpatient visits were the major component
of costs (40%) in the SYS arm. In both arms, non-protocol
chemotherapy treatment given after progression accounted for
approximately half of all outpatient care costs. Compared to sys-
temic 5-ﬂuorouracil and leucovorin, hepatic artery infusion of
ﬂoxuridine increased quality-adjusted survival by 0.46 quality-
adjusted life years, at an incremental cost of $50,867. Most of
the difference in costs occurred early, and was attributable to
higher inpatient care and surgery costs. The incremental cost-
effectiveness ratio (ICER) was $112,924 per quality-adjusted life
year. The bootstrap-derived distribution of ICER was quite
precise, with only 28% and 90% of simulations falling under
$100,000/QALY and $200,000/QALY, respectively. The magni-
tude of the ICER was robust in sensitivity analyses. CONCLU-
SIONS: Hepatic artery infusion for metastatic colorectal cancer
resulted in a substantial increase in quality-adjusted survival at
an ICER that compares favorably with other widely used cancer
treatments in the United States. These results create a benchmark
against which the costs and cost-effectiveness of new agents can
and should be evaluated.
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OBJECTIVE: Anemia, a common complication of chemother-
apy, is often treated with erythropoiesis-stimulating proteins.
The objective of this study was to assess the cost-effectiveness of
once every three weeks (Q3W) 500mg Aranesp® (darbepoetin
alfa) administration compared to a weekly 150mg (QW) regimen
from a French societal perspective. METHOD: A decision-tree
model with a 16-week time horizon was developed in Excel®.
This model included the possibility to adapt darbepoetin alfa
dosing based on hemoglobin (Hb) criteria reported in guidelines.
The transition probabilities, the number of days with Hb ≥ 11
g/dL (effectiveness measure), and the units of blood transfused
were extracted from a randomized clinical trial. Unit costs were
applied to medical resources used (transfusions, darbepoetin
alfa, physician visits, hospitalizations, and administration time
by health care professionals) and patients’ time. Literature data,
validated by two French clinical experts, was used for inputs
regarding resource use. Time was valued at gross hourly wage
rate. Both time and medical costs were extracted from ofﬁcial
sources (AMELI; INSEE) and adjusted to 2005 values. A 5000-
replication probabilistic sensitivity analysis was performed with
@RISK® using distributions for both probabilities and time.
RESULTS: The effectiveness was similar between the two arms.
Switching patients from QW to Q3W resulted in a gain of 2.3
days with Hb ≥ 11g/dL (95% CI: -3.3; 7.6). Total costs were
slightly lower for Q3W (€4616 [95% CI: 4303; 4959]) compared
to QW (€4856 [95% CI: €4488; 5258]). Probabilistic sensitivity
analysis revealed 68% of replications with higher effectiveness
and lower costs for Q3W treatment (dominant); 11% with both
higher effectiveness and costs; 4% where Q3W was dominated
by QW and 17% showed both lower effectiveness and costs.
CONCLUSION: This analysis provides probabilistic informa-
tion to decision makers about the health economic impact of dar-
bepoetin alfa Q3W. A decision in favor of Q3W is more likely
to be beneﬁcial from a health economic viewpoint.
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OBJECTIVE: To estimate the cost-effectiveness of adjuvant
treatment with exemestane vs. tamoxifen for early-stage breast
cancer after 2–3 years treatment with tamoxifen, in Spain.
METHODS: A Markov state-transition model was performed
from the National Health System perspective, and simulates the
long-term outcomes over 10 and 20 years. The primary outcome
was the incremental cost-effectiveness of exemestane scheme in
terms of cost per quality-adjusted life year (QALY) gained. The
transition probabilities between health states (disease-free sur-
vival with or without complications, local recurrence, contralat-
eral breast cancer, systemic recurrence or dead) were derived
from the Intergroup Exemestane Study (IES) trial and from sec-
ondary Spanish sources. The costs associated with chemother-
apy and complications (bone fractures, vaginal bleeding, venous
thromboembolism, myocardial infarction) and unit costs
(€2005) were obtained from Spanish treatment guidelines and
Spanish health costs databases. A literature review was con-
ducted to derive the utility data. RESULTS: The average addi-
tional QALY per exemestane-treated patients were 0.200 and
0.557, for 10 and 20 years, respectively, compared with that of
tamoxifen alone scheme. The additional cost per QALY gained
obtained with exemestane was €70,990 and €39,170, respec-
tively. The sensitivity analyses conﬁrmed the robustness of the
base case analysis. CONCLUSIONS: According to this model,
adjuvant exemestane therapy after 2–3 years of tamoxifen
therapy signiﬁcantly improved disease-free survival as compared
